Balwinder Singh1, Michelle M Mielke2, Ajay K Parsaik3, Ruth H Cha4, Rosebud O Roberts2, Paul D Scanlon5, Yonas E Geda6, Teresa J Christianson4, V Shane Pankratz4, Ronald C Petersen2. 1. Department of Neurology, Mayo Clinic, Rochester, Minnesota2Department of Clinical Neuroscience, University of North Dakota School of Medicine and Health Sciences, Fargo. 2. Department of Neurology, Mayo Clinic, Rochester, Minnesota3Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. 3. Department of Neurology, Mayo Clinic, Rochester, Minnesota4Department of Psychiatry and Behavior Sciences, University of Texas Medical School, Houston. 4. Division of Biomedical Statistics and Informatics, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota. 5. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota. 6. Department of Psychiatry and Psychology, Mayo Clinic, Scottsdale, Arizona8Department of Neurology, Mayo Clinic, Scottsdale, Arizona.
Abstract
IMPORTANCE: Previous studies suggest cross-sectional associations between a diagnosis of chronic obstructive pulmonary disease (COPD) and mild cognitive impairment (MCI). However, few studies have assessed whether COPD, a potentially modifiable factor, is associated with an increased risk for MCI and whether the relation is specific to the type of MCI. OBJECTIVE: To investigate whether a diagnosis of COPD and duration of COPD are associated with an increased risk for incident MCI and MCI subtypes (amnestic MCI [A-MCI] and nonamnestic MCI [NA-MCI]). DESIGN, SETTING, AND PARTICIPANTS: A prospective population-based cohort from the Mayo Clinic Study on Aging. We included 1425 cognitively normal individuals aged 70 to 89 years who were randomly selected from Olmsted County, Minnesota, on October 1, 2004, using the medical records linkage system. At baseline and every 15 months thereafter, participants underwent assessment with a nurse interview, neurologic examination, and neuropsychological testing. A diagnosis of COPD was confirmed via medical record review. A baseline diagnosis of COPD and duration of COPD were examined as risk factors for MCI and MCI subtypes using Cox proportional hazards models and adjusting for demographic variables and medical comorbidities, with age as the time scale. EXPOSURE: A baseline diagnosis of COPD and duration of COPD. MAIN OUTCOMES AND MEASURES: Incident MCI, A-MCI, and NA-MCI. RESULTS: Of the 1425 participants with normal cognition at baseline, 370 developed incident MCI. The median duration of follow-up was 5.1 years (interquartile range, 3.8-5.4 years). A diagnosis of COPD significantly increased the risk for NA-MCI by 83% (hazard ratio, 1.83 [95% CI, 1.04-3.23]), but not of any MCI or A-MCI in multivariate analyses. We found a dose-response relationship such that individuals with COPD duration of longer than 5 years at baseline had the greatest risk for any MCI (hazard ratio, 1.58 [95% CI, 1.04-2.40]) and NA-MCI (2.58 [1.32-5.06]). CONCLUSIONS AND RELEVANCE: A diagnosis of COPD is associated with an increased risk for MCI, particularly NA-MCI. We have found a dose-response relationship between COPD duration and risk for MCI. These findings highlight the importance of COPD as a risk factor for MCI and may provide a substrate for early intervention to prevent or delay the onset and progression of MCI, particularly NA-MCI.
RCT Entities:
IMPORTANCE: Previous studies suggest cross-sectional associations between a diagnosis of chronic obstructive pulmonary disease (COPD) and mild cognitive impairment (MCI). However, few studies have assessed whether COPD, a potentially modifiable factor, is associated with an increased risk for MCI and whether the relation is specific to the type of MCI. OBJECTIVE: To investigate whether a diagnosis of COPD and duration of COPD are associated with an increased risk for incident MCI and MCI subtypes (amnestic MCI [A-MCI] and nonamnestic MCI [NA-MCI]). DESIGN, SETTING, AND PARTICIPANTS: A prospective population-based cohort from the Mayo Clinic Study on Aging. We included 1425 cognitively normal individuals aged 70 to 89 years who were randomly selected from Olmsted County, Minnesota, on October 1, 2004, using the medical records linkage system. At baseline and every 15 months thereafter, participants underwent assessment with a nurse interview, neurologic examination, and neuropsychological testing. A diagnosis of COPD was confirmed via medical record review. A baseline diagnosis of COPD and duration of COPD were examined as risk factors for MCI and MCI subtypes using Cox proportional hazards models and adjusting for demographic variables and medical comorbidities, with age as the time scale. EXPOSURE: A baseline diagnosis of COPD and duration of COPD. MAIN OUTCOMES AND MEASURES: Incident MCI, A-MCI, and NA-MCI. RESULTS: Of the 1425 participants with normal cognition at baseline, 370 developed incident MCI. The median duration of follow-up was 5.1 years (interquartile range, 3.8-5.4 years). A diagnosis of COPD significantly increased the risk for NA-MCI by 83% (hazard ratio, 1.83 [95% CI, 1.04-3.23]), but not of any MCI or A-MCI in multivariate analyses. We found a dose-response relationship such that individuals with COPD duration of longer than 5 years at baseline had the greatest risk for any MCI (hazard ratio, 1.58 [95% CI, 1.04-2.40]) and NA-MCI (2.58 [1.32-5.06]). CONCLUSIONS AND RELEVANCE: A diagnosis of COPD is associated with an increased risk for MCI, particularly NA-MCI. We have found a dose-response relationship between COPD duration and risk for MCI. These findings highlight the importance of COPD as a risk factor for MCI and may provide a substrate for early intervention to prevent or delay the onset and progression of MCI, particularly NA-MCI.
Authors: K Yaffe; K Lindquist; B W Penninx; E M Simonsick; M Pahor; S Kritchevsky; L Launer; L Kuller; S Rubin; T Harris Journal: Neurology Date: 2003-07-08 Impact factor: 9.910
Authors: John E Morley; John C Morris; Marla Berg-Weger; Soo Borson; Brian D Carpenter; Natalia Del Campo; Bruno Dubois; Keith Fargo; L Jaime Fitten; Joseph H Flaherty; Mary Ganguli; George T Grossberg; Theodore K Malmstrom; Ronald D Petersen; Carroll Rodriguez; Andrew J Saykin; Philip Scheltens; Eric G Tangalos; Joe Verghese; Gordon Wilcock; Bengt Winblad; Jean Woo; Bruno Vellas Journal: J Am Med Dir Assoc Date: 2015-09-01 Impact factor: 4.669
Authors: Maria Vassilaki; Jeremiah A Aakre; Ruth H Cha; Walter K Kremers; Jennifer L St Sauver; Michelle M Mielke; Yonas E Geda; Mary M Machulda; David S Knopman; Ronald C Petersen; Rosebud O Roberts Journal: J Am Geriatr Soc Date: 2015-08-27 Impact factor: 5.562
Authors: Maria Vassilaki; Jeremiah A Aakre; Michelle M Mielke; Yonas E Geda; Walter K Kremers; Rabe E Alhurani; Mary M Machulda; David S Knopman; Ronald C Petersen; Val J Lowe; Clifford R Jack; Rosebud O Roberts Journal: Neurology Date: 2016-04-13 Impact factor: 9.910
Authors: Pamela L Lutsey; Nemin Chen; Maria C Mirabelli; Kamakshi Lakshminarayan; David S Knopman; Keith A Vossel; Rebecca F Gottesman; Thomas H Mosley; Alvaro Alonso Journal: Am J Respir Crit Care Med Date: 2019-06-01 Impact factor: 21.405
Authors: Robert A Wise; Russell A Acevedo; Antonio R Anzueto; Nicola A Hanania; Fernando J Martinez; Jill A Ohar; Donald P Tashkin Journal: Chronic Obstr Pulm Dis Date: 2016-11-15
Authors: Anna Croghan; Amanda Brunette; Kristen E Holm; Elizabeth Kozora; David J Moser; Frederick S Wamboldt; Kimberly Meschede; Barry J Make; James D Crapo; Howard D Weinberger; Kerrie L Moreau; Russell P Bowler; Karin F Hoth Journal: Int J Behav Med Date: 2019-12
Authors: Mary Ganguli; Yichen Jia; Tiffany F Hughes; Beth E Snitz; Chung-Chou H Chang; Sarah B Berman; Kevin J Sullivan; M Ilyas Kamboh Journal: J Am Geriatr Soc Date: 2018-11-16 Impact factor: 5.562